Benefits
Skin Protection Against UV Damage
PL has strong antioxidant properties, reducing UV-induced skin damage by up to 80% in some studies. It decreases sunburn severity, protects against photoaging (wrinkles, pigmentation), and may lower the risk of skin cancer by neutralizing free radicals and reducing DNA damage. Studies show it preserves skin cells (Langerhans cells) and reduces inflammation post-UV exposure.
Anti-Inflammatory Effects
PL inhibits pro-inflammatory molecules like TNF-alpha and reduces oxidative stress, which may help with conditions like psoriasis, eczema, and vitiligo. Clinical trials indicate it can improve symptoms in these conditions when taken orally or applied topically.
Photodermatosis Management
For conditions like polymorphous light eruption (PMLE), PL reduces symptoms such as itching and rashes triggered by sun exposure. It’s been shown to allow longer sun exposure without reactions in sensitive individuals.
Antioxidant Support
PL contains phenolic compounds (e.g., ferulic acid, caffeic acid) that scavenge free radicals, protecting cells from oxidative stress. This supports overall skin health and may have broader anti-aging benefits.
Immune Modulation
PL may enhance immune function by protecting immune cells and reducing systemic inflammation, potentially aiding autoimmune skin disorders.
Potential Anticancer Properties
Preliminary studies suggest PL’s antioxidant and DNA-protective effects could reduce the risk of UV-related skin cancers, though more research is needed
Mechanism of action
Antioxidant Activity
PL contains phenolic compounds (e.g., ferulic acid, caffeic acid, chlorogenic acid) that act as potent antioxidants. These neutralize reactive oxygen species (ROS) generated by UV radiation or other stressors, preventing oxidative damage to DNA, lipids, and proteins in skin cells. This reduces UV-induced cellular apoptosis and photoaging.
Photoprotection
Reducing cyclobutane pyrimidine dimers (CPDs), which are DNA lesions caused by UV exposure, thus lowering the risk of mutations and skin cancer. Preserving Langerhans cells (immune cells in the skin) critical for immune surveillance, which are typically depleted by UV radiation. Decreasing erythema (redness) by limiting UV-induced vasodilation and inflammation.
Anti-Inflammatory Effects
PL suppresses pro-inflammatory cytokines (e.g., TNF-alpha, IL-6) and reduces the expression of inflammatory mediators like cyclooxygenase-2 (COX-2). This mitigates inflammation in conditions like psoriasis, eczema, or UV-induced sunburn.
Immune Modulation
By protecting immune cells and regulating inflammatory pathways, PL supports immune homeostasis, potentially benefiting autoimmune skin disorders (e.g., vitiligo, polymorphous light eruption).
Matrix Protection
PL inhibits matrix metalloproteinases (MMPs), enzymes that degrade collagen and elastin in the skin due to UV exposure. This helps maintain skin structure and prevents photoaging signs like wrinkles.
DNA Repair Support
PL enhances DNA repair mechanisms by promoting the activity of nucleotide excision repair pathways, which correct UV-induced DNA damage.
Clinical trials
Randomized, double-blind, placebo-controlled trial in 40 healthy adults examining safety and efficacy of oral PLE supplementation.
40 healthy adults.
PLE was safe and produced modest photoprotective effects vs placebo. Generally well-tolerated.
Clinical trial in 22 subjects (Fitzpatrick skin types I-III) irradiated with visible light, UVA1, and UVB before and after oral PLE supplementation.
22 fair-skinned adults.
PLE modestly increased minimal erythemal dose (MED) — providing photoprotective effect. Critical caveat: not a sunscreen replacement — modest oral photoprotection that should be adjunctive to topical SPF. Topical sunscreen remains the foundation of UV protection.
Randomized, double-blind, placebo-controlled trial at National Skin Centre, Singapore, in 40 patients with polymorphic light eruption (a photosensitivity disorder).
40 PLE patients.
PLE supplement modestly reduced disease severity and improved symptoms vs placebo. Niche dermatology application; PLE (the disease) is a photosensitivity disorder requiring multidisciplinary care.
Randomized, controlled trial in 61 patients with polymorphic light eruption receiving hydrophilic extract of Polypodium leucotomos vs control.
61 PLE patients.
Hydrophilic PLE reduced photosensitivity symptoms vs control. Adds support for PLE in photosensitivity disorders.
Randomized, double-blind, placebo-controlled trial in 105 patients with atopic dermatitis receiving PLE vs placebo.
105 atopic dermatitis patients.
PLE modestly improved atopic dermatitis severity vs placebo. Note: atopic dermatitis is primarily managed with topical emollients, corticosteroids, calcineurin inhibitors (tacrolimus, pimecrolimus), and now JAK inhibitors and biologics (dupilumab) — strong evidence-based therapy. PLE adjunctive at most.
Randomized, double-blind, placebo-controlled trial in 50 patients with vitiligo receiving narrow-band UVB phototherapy + PLE vs placebo.
50 vitiligo patients.
PLE adjunct to NB-UVB modestly improved repigmentation vs UVB alone. Niche application; vitiligo treatment requires dermatology specialist care.
Randomized clinical trial in healthy volunteers receiving oral PLE before UVA exposure. Outcomes: mitochondrial DNA 'common deletion' marker of UV damage.
Healthy volunteers.
PLE reduced UVA-induced mtDNA 'common deletion' vs placebo. Mechanistic confirmation of UV-protective effects at molecular level.
Clinical trial in 25 patients with idiopathic photodermatoses (solar urticaria, chronic actinic dermatitis) receiving oral PLE.
25 idiopathic photodermatosis patients.
PLE modestly improved photoprotection in this niche population. Open-label/uncontrolled — lower evidence quality.